Released Presentations
PLENARY SESSIONS

FIRST PLENARY SESSION: ACCELERATING CURES: ADDRESSING UNMET PATIENT NEED OR PUTTING PATIENTS AT RISK?

Presentation
Eleanor M. Perfetto, Senior Vice President, Strategic Initiatives, National Health Council, Washington, DC and Professor, Pharmaceutical Health Services Research, School of Pharmacy, University of Maryland, Baltimore, MD, USA
Presentation
Patricia Furlong, Founding President & Chief Executive Officer, Parent Project Muscular Dystrophy (PPMD), Middletown, OH, USA
Presentation
Jerry Avorn, Professor of Medicine, Harvard Medical School and Chief of the Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women’s Hospital, Boston, MA, USA
Presentation
Scott Gottlieb, Resident Fellow, American Enterprise Institute, Washington, DC, USA

 

SECOND PLENARY SESSION: MAKING MEDICAL DECISIONS IN AN IRRATIONAL WORLD

Presentation
Bradley C. Martin, Professor & Head, Division of Pharmaceutical Evaluation and Policy, University of Arkansas for Medical Sciences College of Pharmacy, Little Rock, AR, USA
Presentation
Douglas E. Hough, Associate Scientist, Department of Health Policy and Management, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, USA
Presentation
David Meltzer, Fannie L. Pritzker Professor of Medicine, Economics, and Public Policy, Chief of the Section of Hospital Medicine, Director of the Center for Health and the Social Sciences, and Chair of the Committee on Clinical and Translational Science, University of Chicago, Chicago, IL, USA

 

THIRD PLENARY SESSION: CONTEMPORARY REGULATORY AND LEGISLATIVE ISSUES IN HEALTH OUTCOMES RESEARCH

Presentation
Marc M. Boutin, Chief Executive Officer, National Health Council, Washington, DC, USA
Presentation
Gregory W. Daniel, Deputy Director, Duke-Robert J. Margolis, MD Center for Health Policy, Duke University, Washington, DC, USA
Presentation
Kay Holcombe, Senior Vice President, Science Policy, BIO, Washington, DC, USA
Presentation
Theresa M. Mullin, Director, Office of Strategic Programs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration (FDA), Silver Spring, MD, USA

 

ISSUE PANEL PRESENTATIONS

IP1 : PAYERS' USE OF INDEPENDENT REPORTS IN DECISION MAKING – WILL THERE BE AN ICER EFFECT?

Presentation
Michael Drummond, Professor of Health Economics, Centre for Health Economics, University of York, Heslington, York, UK
Presentation
Michael Barry, Clinical Director, National Centre for Pharmacoeconomics, Dublin, Ireland
Presentation
Allen Lising, Managing Director, Dymaxium Inc, Toronto, ON, Canada
Presentation
Federico Augustovski, Director, Health Technology Assessment and Health Economic Department, Institute for Clinical Effectiveness and Health Policy (IECS), University of Buenos Aires, Buenos Aires, Argentina

 

IP2 : ARE WE READY FOR A CURE? KEY VALUE DEMONSTRATION AND POLICY CONSIDERATIONS FOR THE NEW WAVE OF POTENTIALLY CURATIVE THERAPIES

Presentation
Gregory W. Daniel, Deputy Director, Duke-Robert J. Margolis, MD Center for Health Policy, Duke University, Washington, DC, USA
Eric Faulkner, Vice President, Precision and Transformative Technology Solutions, Evidera, Durham, NC, USA
Tamara Syrek Jensen, Acting Director, Coverage and Analysis Group, Center for Medicare and Medicaid Services, Baltimore, MD, USA
Simu K. Thomas, Global Head, Market Access and HEOR, Cell and Gene Therapies Unit, Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA

 

IP3 : WHAT’S NEXT FOR VALUE FRAMEWORKS FOR PRESCRIPTION DRUGS?

Presentation
Lowell E. Schnipper, Theodore and Evelyn Berenson Professor of Medicine, Harvard Medical School, Clinical Director; Cancer Center, and Chief, Hematology/Oncology Division, Beth Israel Deaconess Medical Center, Boston, MA, USA
Presentation
Joshua Ofman, Senior Vice President, Global Value and Access and Policy, Amgen, Thousand Oaks, CA, USA
Presentation
Dan Ollendorf, Chief Scientific Officer, Institute for Clinical and Economic Review, Boston, MA, USA

 

IP4 : ASSESSING THE VALUE OF MEDICAL DEVICES – CHOOSING THE BEST PATH FORWARD: WHERE DO WE GO FROM HERE?

Presentation
Andrew M. Baker, Director, Health Policy & Reimbursement, Stryker, Mahwah, NJ, USA
Presentation
Bruce Gingles, Vice President - Global Technology Assessment and Healthcare Policy, Cook Medical, Bloomington, IN, USA
Nneka C Onwudiwe, PRO/PE Regulatory Reviewer, Office of Prescription Drug Promotion, CDER, U.S. Food and Drug Administration, Silver Spring, MD, USA

 

IP5 : USE OF REAL-WORLD EVIDENCE IN PAYER DECISION MAKING: FACT OR FICTION?

Presentation
John W. McKnight, Director, HPS Clinical Strategies, Humana, Louisville, KY, USA
Steven G. Avey, Vice President, Specialty Pharmacy, MedImpact, San Diego, CA, USA
Daniel Malone, Professor of Pharmacy, College of Pharmacy and Associate Professor, Mel & Enid Zuckerman College of Public Health, University of Arizona, Tucson, AZ, USA
Craig Mattson, Senior Director, Formulary Development, Prime Therapeutics, Eagan, MN, USA

 

IP6 : MULTI-INDICATION PRICING: DO WE WANT IT? CAN WE OPERATIONALIZE IT?

Presentation
Adrian Towse, Director, Office of Health Economics, London, UK
Presentation
Ansgar Hebborn, Head, Global HTA & Payment Policy, Global Pricing & Market Access, F. Hoffmann-La Roche AG, Basel, Switzerland
Presentation
Bill Dreitlein, Director of Pharmaceutical Policy, Institute for Clinical and Economic Review, Boston, MA, USA
Presentation
Sean Karbowicz, Director, Innovation and Pharmacy Policy, OmedaRx, Portland, OR, USA

 

IP7 : PHARMACEUTICAL PRICING IN THE UNITED STATES: ARE WE BALANCING INNOVATION AND AFFORDABILITY?

Presentation
Dan Ollendorf, Chief Scientific Officer, Institute for Clinical and Economic Review, Boston, MA, USA

 

IP8 : INCORPORATING REAL-WORLD EVIDENCE FOR REGULATORY DECISION MAKING: IS THE DEVICE ECOSYSTEM READY?

Presentation
Sharon-Lise T. Normand, Professor, Department of Health Care Policy, Harvard Medical School, Boston, MA, USA
Presentation
Danica Marinac-Dabic, Director, Division of Epidemiology, CDRH, U.S. Food and Drug Administration, Silver Spring, MD, USA
Presentation
Gerry Gray, Acting Director, Division of Biostatistics, CDRH, U.S. Food and Drug Administration, Silver Spring, MD, USA
Presentation
Jeff Dunkel, Vice President, Titan Spine, Mequon, WI, USA

 

IP9 : NEXT GENERATION COMPARATIVE EFFECTIVENESS RESEARCH – ARE WE GETTING ORGANIZED TO FACILITATE RESEARCH FOR THE INDIVIDUAL PATIENT?

Presentation
Kristian Thorlund, Vice President of Health Analytics, Precision Health Economics, Vancouver, BC, Canada
Presentation
Rachael Fleurence, Program Director of Comparative Effectiveness Research Methods and Infrastructure Program, Patient Centered Outcomes Research Institute (PCORI), Washington, DC, USA

 

IP10 : COST-EFFECTIVENESS THRESHOLDS: SHOULD WE BE GENERATING MORE EMPIRICAL EVIDENCE AND, IF SO, HOW?

Presentation
Marta Soares, Senior Research Fellow, Team for Economic Evaluation and Health Technology Assessment (TEEHTA), Centre for Health Economics, University of York, Heslington, York, UK
Presentation
Anirban Basu, Professor & Director, Pharmaceutical Outcomes Research and Policy Program, University of Washington, Seattle, WA, USA
Presentation
Mark Sculpher, Professor of Health Economics, Centre for Health Economics & Director, Programme on Economic Evaluation and Health Technology Assessment, University of York, Heslington, York, UK
Presentation

 

IP11 : HOW DO CULTURE, VALUES, AND INSTITUTIONAL CONTEXT SHAPE THE METHODS AND USE OF ECONOMIC EVALUATION?

Presentation
Michael Drummond, Professor of Health Economics, Centre for Health Economics, University of York, Heslington, York, UK
Presentation
Peter J. Neumann, Professor & Director, Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies,Tufts Medical Center, Boston, MA, USA
Presentation
Robert W Dubois, Chief Science Officer, National Pharmaceutical Council, Washington, DC, USA

 

IP12 : MULTI-CRITERIA DECISION ANALYSIS: A NEW PARADIGM IN HEALTH CARE DECISION MAKING? WHAT ARE THE CURRENT STATUS, CHALLENGES, AND OPPORTUNITIES?

Presentation
Kevin Marsh, Executive Director, Evidera, London, UK
Presentation
Mireille M. Goetghebeur, Global Scientist, LASER Analytica and School of Public Health, University of Montreal, Montreal, QC, Canada
Presentation
James Dolan, Professor, University of Rochester, Rochester, NY, USA
Presentation
Mabel Moreno Viscaya, Senior Economist, Instituto de Evaluación Tecnológica en Salud (IETS), Bogata, Colombia

 

IP13 : PERFORMANCE-BASED RISK-SHARING ARRANGEMENTS: WHAT ARE THE VIEWS FROM THE NEGOTIATING TABLE?

Presentation
Kathleen E. Hughes, Vice President, Health Economics and Outcomes Research, Avalere Health LLC, Washington, DC, USA
Michael L. Ryan, Senior Vice President, Bristol-Myers Squibb, Princeton, NJ, USA
Michael S. Sherman, Senior Vice President & Chief Medical Officer, Harvard Pilgrim Health Care, Wellesley, MA, USA
Jim Clement, Executive Director, Industry Relations & Financial Strategy, Aetna, Hartford, CT, USA

 

IP15 : SOCIAL LISTENING FOR SAFETY OUTCOMES AND PHARMACOECONOMIC CONSIDERATIONS: HAS THE TIME COME?

Presentation
Nabarun Dasgupta, Chief Product Officer, Epidemico, Boston, MA, USA
Presentation
Jeff Terkowitz, Director, Product Management, Inspire, Arlington, VA, USA
Presentation
Robert Ball, Deputy Director, Office of Surveillance and Epidemiology, CDER, U.S. Food and Drug Administration, Silver Spring, MD, USA

 

IP16 : ARE ALTERNATIVE FINANCING APPROACHES NEEDED FOR INNOVATIVE THERAPIES?

Presentation
Noam Y. Kirson, Vice President, Analysis Group, Inc., Boston, MA, USA
John Michael O'Brien, Vice President, Public Policy, CareFirst BlueCross BlueShield, Washington, DC, USA
Krista M Ward, Senior Director, Medicaid, Express Scripts, Saint Louis, MO, USA

 

IP17 : HARNESSING BIG DATA FOR WOUND HEALING RESEARCH: WHICH IS MORE RELEVANT IN THE QUEST FOR EVIDENCE – REAL-WORLD PATIENT-CENTERED OUTCOMES OR RANDOMIZED TRIALS?

Presentation
Marcia Nusgart, Executive Director, Alliance of Wound Care Stakeholders, Bethesda, MD, USA
Elise Berliner, Director of the Technology Assessment Program, Center for Outcomes and Evidence, Agency for Healthcare Research and Quality, Rockville, MD, USA
Caroline E. Fife, Professor of Geriatrics, Department of Internal Medicine, Baylor College of Medicine, Houston, TX, USA
Marissa J. Carter, President, Strategic Solutions Inc., Cody, WY, USA

 

IP18 : PRECISION MEDICINE: THE END OF OUTCOMES RESEARCH?

Presentation
Fadia T. Shaya, Professor, Associate Director, Pharmaceutical Health Services Research, University of Maryland School of Pharmacy, Baltimore, MD, USA
John Watkins, Formulary Manager, Premera Blue Cross, Mountlake Terrace, WA, USA
Susan Snyder, Research Investigator & Health Economist, Center for Health Research, Geisinger Health System, Danville, PA, USA

 

IP19 : CREATING AND ANALYZING SYMPTOM ENDPOINTS WHEN THERE IS SYMPTOM HETEROGENEITY ACROSS PATIENTS: WHAT ARE THE POTENTIAL SOLUTIONS?

Presentation
Karon F. Cook, Research Professor, Department of Medical Social Sciences, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
Presentation
Chad Gwaltney, Research Assistant Professor, Brown University, Providence, RI, USA
Presentation
Matthew Reaney, Senior Scientist, ERT, Peterborough, UK

 

WORKSHOP PRESENTATIONS

W1 : PROMOTING THE SAFE USE OF MEDICATIONS AND ENHANCING UNDERSTANDING OF STAKEHOLDERS’ OPINIONS

Presentation
Christine S. Lee, Health Scientist, CDER/PASE, U.S. Food and Drug Administration, Silver Spring, MD, USA
Junyang Wang, Health Scientist, CDER/PASE, U.S. Food and Drug Administration, Silver Spring, MD, USA
David Smith, Senior Researcher, Kaiser, Portland, OR, USA
Deb Pasko, Director, Center on Medication Safety and Quality, ASHP, Bethesda, MD, USA

 

W2 : RISK-SHARING AGREEMENTS FOR MANUFACTURERS AND COMMERCIAL PAYERS IN THE UNITED STATES: HOW CAN THEORY HELP PRACTICE? DESIGN AND ALIGNING INCENTIVES ARE KEY

Presentation
Adrian Towse, Director, Office of Health Economics, London, UK
Rajiv Mallick, Senior Director, Health Economics and Outcomes Research, BTG International Inc., West Conshohocken, PA, USA
Pete Fullerton, Principal, Strategic Pharmacy Innovations, Seattle, WA, USA
Lou Garrison, Professor, Pharmaceutical Outcomes Research and Policy Program, University of Washington, Seattle, WA, USA

 

W3 : BIOSIMILARS: CURRENT DEVELOPMENTS AND REAL-WORLD EVIDENCE GENERATION

Presentation
Jaclyn L. Bosco, Director of Epidemiology, Real-World & Late Phase Research, Quintiles, Cambridge, MA, USA
Presentation
Gregory W. Daniel, Deputy Director, Duke-Robert J. Margolis, MD Center for Health Policy, Duke University, Washington, DC, USA
Presentation
Catherine A. Panozzo, Instructor, Department of Population Medicine, Harvard Pilgrim Health Care Institute/Harvard Medical School, Boston, MA, USA
Presentation
Rachael Fleurence, Program Director of Comparative Effectiveness Research Methods and Infrastructure Program, Patient Centered Outcomes Research Institute (PCORI), Washington, DC, USA

 

W4 : THE SCIENCE AND ART OF PERFORMING NETWORK META-ANALYSES (NMA) TO AID DECISION MAKING FOR TYPE 2 DIABETES TREATMENT: HOW DOES IT WORK IN PRACTICE?

Presentation
Melanie Schroeder, Outcomes Research Associate, Janssen-Cilag UK, High Wycombe, UK
Keith Abrams, Professor of Medical Statistics, Health Sciences, Health Sciences, University of Leicester, Leicester, UK
Maud Pacou, Team Leader, Statistics, Amaris, Paris, France
Robert Cuddihy, Vice President, Global Medical Affairs CVM, Janssen Global Services, LLC, Raritan, NJ, USA

 

W5 : CONSTRAINED OPTIMIZATION: WHY MAKING PIZZA AND MAXIMIZING HEALTH CARE VALUE ARE THE SAME PROBLEM

Presentation
Deborah A. Marshall, Canada Research Chair, Health Services and Systems Research & Associate Professor, Department of Community Health Sciences, Faculty of Medicine, University of Calgary, Alberta Bone and Joint Health Institute, Calgary, AB, Canada
Kalyan Pasupathy, Associate Professor, Health Care Policy & Research, Mayo Clinic, Rochester, MN, USA
William Crown, Chief Scientific Officer, Optum Labs, Cambridge, MA, USA
Jonathan C. Tosh, Senior Health Economist, DRG Abacus, Manchester, UK

 

W6 : EQUIVALENCE OF PAPER AND ELECTRONIC MODES OF PATIENT-REPORTED OUTCOME DATA COLLECTION: AN ANSWERED QUESTION

Presentation
Stephen Joel Coons, Executive Director, PRO Consortium, Critical Path Institute, Tucson, AZ, USA
Paul O'Donohoe, Director, Health Outcomes, CRF Health, London, UK
Jason Lundy, Principal, Outcometrix, Tucson, AZ, USA

 

W7 : EXPLORING AND LEVERAGING KNOWN RESOURCES TO SUPPORT PEDIATRIC CLINICAL OUTCOMES ASSESSMENT (COA) DEVELOPMENT

Presentation
Diane M. Turner-Bowker, Director, Patient-Centered Outcomes, Adelphi Values, Boston, MA, USA
Meaghan Krohe, Associate Director, Patient-Centered Outcomes, Adelphi Values, Boston, MA, USA
Christine Archuleta Banderas, Child Life Specialist, Mattel Children's Hospital, UCLA, Los Angeles, CA, USA

 

W8 : ESTABLISHING THE VALUE OF DIAGNOSTIC AND PROGNOSTIC TOOLS IN HEALTH TECHNOLOGY ASSESSMENT

Presentation
Andrew Briggs, Visiting Investigator, Center for Health Policy and Outcomes, Department of Epidemiology & Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA & William R. Lindsey Chair of Health Economics & Health Technology Assessment, Institute of Health & Wellbeing, University of Glasgow, Glasgow, UK
Presentation
Marta Soares, Senior Research Fellow, Team for Economic Evaluation and Health Technology Assessment (TEEHTA), Centre for Health Economics, University of York, Heslington, York, UK
Presentation
Susan Griffin, Senior Research Fellow, Centre for Health Economics, University of York, Heslington, York, UK

 

W9 : FIVE YEARS OF HEALTH CARE HORIZON SCANNING FOR AHRQ – RESULTS AND LESSONS LEARNED

Presentation
Marcus Lynch, Senior Clinical Writer, Technology Assessment, ECRI Institute, Plymouth Meeting, PA, USA
Elise Berliner, Director, Technology Assessment, Center for Evidence and Practice Improvement, Agency for Healthcare Research and Quality, Rockville, MD, USA
Karen Schoelles, Director, ECRI Institute-Penn Medicine Evidence-based Practice Center, Technology Assessment, ECRI Institute, Plymouth Meeting, PA, USA
Diane Robertson, Director, ECRI Institute Health Technology Assessment Information Service, Technology Assessment, ECRI Institute, Plymouth Meeting, PA, USA

 

W10 : REAL-WORLD DATA AND REAL-WORLD EVIDENCE IN LATIN AMERICA: IT TAKES TWO TO TANGO

Presentation
Marcelo Eidi Nita, Lecturer & Researcher in HTA and PCDT, IECS, HAOC, and FIPE, Sao Paulo, Brazil
Presentation
Paulo Vaz, CEO, HEADS, Sao Paulo, Brazil
Presentation
David Thompson, Senior Vice President, inVentiv Health, Burlington, MA, USA

 

W13 : PATIENTS AS PARTNERS IN RESEARCH – MAKING IT A REALITY

Presentation
Rachel Harrington, Senior Research Alliances Manager, Health Economics and Clinical Outcomes Research, Astellas Medical Affairs Americas, Northbrook, IL, USA
Robert N. McBurney, Chief Executive Officer, Accelerated Cure Project for Multiple Sclerosis, Waltham, MA, USA
Holly Peay, Principal Investigator, DuchenneConnect Network, Parent Project Muscular Dystrophy, and Research Scientist, RTI International, Research Triangle Park, NC, USA
Alfonso Aguarón, Project Manager, Myeloma Patients Europe, Madrid, Spain

 

W15 : IS VALUE TRULY IN THE EYE OF THE BEHOLDER? ANALYZING THE HETEROGENEITY OF OUTPUTS FROM ASCO, NCCN AND DRUGABACUS ONCOLOGY VALUE FRAMEWORKS AND EXPLORING IMPLICATIONS FOR CANCER DRUG DEVELOPMENT

Presentation
Vikas Chawla, Consultant, Quintiles Advisory Services, New York, NY, USA
Presentation
Emily Hawryluk, Manager, Quintiles Advisory Services, New York, NY, USA
Presentation
Craig White, PhD Candidate, Harvard University, Cambridge, MA, USA
John J. Doyle, Senior Vice President & Managing Director for Value & Outcomes, Quintiles Advisory Services, NY, New York, NY, USA

 

W16 : VISUALIZING DATA FOR HYPOTHESIS GENERATION USING LARGE-VOLUME HEALTH CARE CLAIMS DATA

Presentation
Eberechukwu Onukwugha, Associate Professor, Pharmaceutical Health Services Research, University of Maryland, Baltimore, MD, USA
Presentation
Margret Bjarnadottir, Assistant Professor, Smith School of Business, University of Maryland, College Park, College Park, MD, USA
Shujia Zhou, Research Associate Professor, Computer Science and Electrical Engineering, University of Maryland, Baltimore County, Baltimore, MD, USA

 

W17 : MEDICAL DEVICE EVALUATIONS VIA COORDINATED REGISTRY NETWORKS: ANALYTICAL AND INFRASTRUCTURE CONSIDERATIONS

Presentation
Sharon-Lise T. Normand, Professor, Department of Health Care Policy, Harvard Medical School, Boston, MA, USA
Presentation
Danica Marinac-Dabic, Director, Division of Epidemiology, CDRH, U.S. Food and Drug Administration, Silver Spring, MD, USA
Presentation
Jeff Dunkel, Vice President, Titan Spine, Mequon, WI, USA

 

W18 : PREDICTING MARKET OUTLOOK: ENHANCING MARKET FORECASTING VIA APPLICATION OF PHARMACOECONOMIC MODELING TECHNIQUES

Presentation
Sean Stern, Research Associate, Modeling & Simulation, Evidera, Bethesda, MD, USA
Baris Deniz, Senior Research Scientist, Modeling & Simulation, Evidera, Bethesda, MD, USA
Steve Peterson, Director, Health Economics and Market Access – Rheumatology, Janssen, Titusville, NJ, USA

 

W19 : PATIENT-CENTERED BENEFIT-RISK ANALYSIS: REGULATORY DEVELOPMENTS AND PROSPECTS

Presentation
Bryan Luce, Senior Advisor, Evidera, Bethesda, MD, USA
Presentation
Martin Ho, Team Leader, Neurologic and Dental Biostatistics, U.S. Food and Drug Administration, Silver Spring, MD, USA

 

W20 : A FRAMEWORK FOR MEASURING MULTIPLE MEDICATION ADHERENCE

Presentation
Tamas Agh, Principal Researcher, Syreon Research Institute, Budapest, Hungary
Priti Pednekar, Graduate Student, Mayes College of Healthcare Business and Policy, University of the Sciences, Philadelphia, PA, USA
Thomas J. Bunz, Director of Analytic Strategy, Aetna Consumer Analytics, Granby, CT, USA
Maria Malmenäs, Director, HEMU, PAREXEL International, Stockholm, Sweden

 

W21 : EMPOWERING PATIENT POPULATIONS WITH PHYSICAL OR COGNITIVE LIMITATIONS THROUGH ELECTRONIC CLINICAL OUTCOME ASSESSMENTS (ECOAS)

Presentation
Paul O'Donohoe, Director, Health Outcomes, CRF Health, London, UK
Chloe Tolley, Senior Research Manager, PCO, Adelphi Values Ltd, Bollington, UK
Jessica L. Abel, Manager, Global Health Economics and Outcomes Research, Allergan plc., Jersey City, NJ, USA

 

W22 : THE OPPORTUNITY FOR USING PATIENT-CENTRIC, COMPARATIVE EFFECTIVENESS AND OUTCOMES RESEARCH DATA: EVOLVING APPROACHES TO VALUE DEMONSTRATION AND PRICING IN THE GLOBAL HEALTH CARE MARKETPLACE

Presentation
Sue Ellen J. Kline, Principal Health Economist, Nucleus X Market Access, Warren, NJ, USA
Paul Hunt, President, Pricing Solutions, Toronto, ON, Canada

 

W23 : METHODOLOGIES FOR EVALUATING GEOSPATIAL ACCESS IN MEDICATION USE STUDIES

Presentation
Rajesh Balkrishnan, Professor, Public Health Sciences, University of Virginia School of Medicine, Charlottesville, VA, USA

 

W24 : MISSING DATA IN OBSERVATIONAL STUDIES

Presentation
William Hawkes, Senior Statistical Scientist, Real-World & Late Phase Research, Quintiles, Cambridge, MA, USA
Xu (Sherry) Yan, Team Leader, Therapeutic Statistics Branch I, Division of Biostatistics OSB/CDRH, U.S. Food and Drug Administration, Silver Spring, MD, USA
Aaron B. Mendelsohn, Director, Epidemiology, Real-World & Late Phase Research, Quintiles, Cambridge, MA, USA
Zhaohui Su, Vice President, Biostatistics, Better Outcomes Corporation, Cambridge, MA, USA

 

W25 : SURVIVAL CURVES WITH NON-RANDOMIZED DESIGNS: HOW TO ADDRESS POTENTIAL BIAS AND INTERPRET ADJUSTED SURVIVAL CURVES

Presentation
Eberechukwu Onukwugha, Associate Professor, Pharmaceutical Health Services Research, University of Maryland, Baltimore, MD, USA
Abdalla Aly, Scientist, Health Economics and Outcomes Research, Pharmerit International, Bethesda, MD, USA
Tony Okoro, Senior Manager, Bristol-Myers Squibb, Plainsboro, NJ, USA
Caitlyn T. Solem, Director, Health Economics and Outcomes Research, Pharmerit International, Bethesda, MD, USA

 

W26 : PATIENTS AS PARTNERS IN THE DEVELOPMENT AND INTERPRETATION OF CLINICAL OUTCOME ASSESSMENTS: METHODS, CHALLENGES, AND BENEFITS

Presentation
Milena Anatchkova, Research Scientist, Outcomes Research, Evidera, Lexington, RI, USA
Linda S. Deal, Senior Director & Head of Patient-Centered Outcomes Measurement, Pfizer, Collegeville, PA, USA
Theresa Mullin, Director, Office of Strategic Programs, U.S. Food and Drug Administration, Silver Spring, MD, USA
Alice Bast, Chief Executive Officer, Beyond Celiac, Ambler, PA, USA

 

W29 : THE HEALTH ECONOMICS AND OUTCOMES RESEARCH APPLICATIONS AND VALUATION OF DIGITAL HEALTH TECHNOLOGIES AND MACHINE LEARNING

Presentation
Mei Sheng Duh, Managing Principal, Analysis Group, Inc., Boston, MA, USA
Presentation
Gigi Yuen-Reed, Senior Research Scientist, IBM Watson Health, Tampa, FL, USA
Presentation
Steven Pashko, Principal Offering Manager, IBM Watson Health – Real World Evidence, Wayne, Philadelphia, PA, USA
Presentation
Sherri Rose, Associate Professor, Department of Health Care Policy, Harvard Medical School, Boston, MA, USA

 

W30 : SECONDARY ANALYSIS OF QUALITATIVE DATA TO INFORM THE DEVELOPMENT OF PATIENT-REPORTED OUTCOME (PRO) INSTRUMENTS

Presentation
Elizabeth Gibbons, Senior Research Scientist, Health Services Research Unit, University of Oxford, Oxford, UK
Paul Swinburn, Research Director, Mapi Group, London, UK
Monica Hadi, Consultant, Mapi Group, London, UK

 

ISPOR FORUMS

F1 : ISSUES TO ADDRESS IN REVISING THE ISPOR CODE OF ETHICS

Presentation
Louise Binder, Project Manager & Health Policy Consultant, CNETS, Toronto, ON, Canada
Jessica Santos, Global Compliance and Quality Director, Kantar Health, Epsom, UK
Francis Palumbo, Professor, School of Pharmacy, University of Maryland, Baltimore, MD, USA
David Thompson, Senior Vice President, Real World Evidence Consulting, inVentivHealth, Burlington, MA, USA
Richard J. Willke, Chief Science Officer, International Society for Pharmecoeconomics and Outcomes Research (ISPOR), Lawrenceville, NJ, USA

 

F2 : CLINICAL OUTCOMES ASSESSMENT (COA) MEASUREMENT IN RARE DISEASE CLINICAL TRIALS – A CASE STUDY ON APPLICATION OF EMERGING GOOD PRACTICES

Presentation
Katy Benjamin, Director, Patient Reported Outcomes, ICON, Bethesda, MD, USA
Laurie Burke, Founder, LORA Group, Royal Oak, MD, USA
Donald L. Patrick, Director, Seattle Quality of Life Group, University of Washington, Seattle, WA, USA
Margaret K. Vernon, Senior Research Scientist, Evidera, London, UK

 

F3 : STATISTICAL ANALYSIS OF DISCRETE-CHOICE EXPERIMENTS: A DISCUSSION OF THE ISPOR CONJOINT ANALYSIS GOOD RESEARCH PRACTICES TASK FORCE REPORT

Presentation
Deborah A. Marshall, Canada Research Chair, Health Services and Systems Research & Associate Professor, Department of Community Health Sciences, Faculty of Medicine, University of Calgary, Alberta Bone and Joint Health Institute, Calgary, AB, Canada
John F.P. Bridges, Associate Professor, Department of Health Policy and Management and International Health, John Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
Maarten J. IJzerman, Full Professor, Epidemiology & HTA & Dean, Health Technology and Services Research Department, MIRA institute for Biomedical Technology and Technical Medicine, University of Twente, Enschede, The Netherlands
Juan Marcos Gonzalez, Senior Research Economist, RTI Health Solutions, Research Triangle Park, NC, USA

 

F4 : ECONOMIC EVALUATION OF VACCINES

Presentation
Josephine A. Mauskopf, Vice President, Health Economics, RTI Health Solutions, Research Triangle Park, NC, USA
Mark Connolly, Guest Researcher, University of Groningen, the Netherlands, and Managing Director, Global Market Access Solutions, LLC, Groningen, The Netherlands
Johan L. Severens, Professor of Evaluation in Health Care, Institute of Health Policy & Management, Institute of Medical Technology Assessment (iMTA), Erasmus University, Rotterdam, The Netherlands
Baudouin Standaert, Health Economics, GlaxoSmithKline Vaccines, Wavre, Belgium

 

F5 : FIT FOR PURPOSE: PREPARING FOR A PROFESSIONAL CAREER

Presentation
Joseph Vandigo, Director, Policy & Research, PhRMA, Washington, DC, USA
Presentation
Selena Daniels, Study Endpoints Reviewer, SEALD, U.S. Food and Drug Administration, Silver Spring, MD, USA
Presentation
Abhishek Chitnis, Associate Director, Johnson & Johnson, Raynham, MA, USA

 

F6 : PATIENT-CENTERED HEALTH CARE IN THE BRICS COUNTRIES

Presentation
Gabriela Tannus, Owner & Health Economics Director, Axia.Bio Group, Miami, FL, USA
Presentation
Kun Zhao, Professor & Director, Division of Health Technology Assessment, China National Health Development, Research Center, National Health and Family Planning Commission (NHFPC), Beijing, China
Presentation
Jitendar Sharma, Head, WHO Collaborating Centre for Priority Medical Devices & Health Technology Policy, NHSRC, New Delhi, India
Presentation
Shelley McGee, Healthcare Policy and Patient Access Manager, Sanofi Pharmaceuticals, Pretoria, South Africa
Presentation
Pavel A. Vorobiev, Chair of Haematology and Geriatrics, I. M. Sechenov First Moscow State Medical University, Moscow, Russian Federation

 

F7 : MOVING TOWARDS AN INTEGRAL APPROACH TO PATIENTS WITH RARE DISEASES: AN INTERNATIONAL PERSPECTIVE

Presentation
Camila Quirland, Researcher, Escuela de Salud Pública, Universidad de Chile, Santiago, Chile
Presentation
Diego Rosselli, Professor of Health Economics, Clinical Epidemiology and Biostatistics, Medical School, Pontificia Universidad Javeriana, Bogota, Colombia

 

F8 : DEVELOPING AND EVALUATING CLINICIAN-REPORTED OUTCOMES (CLINROS) – A CASE STUDY ON APPLICATION OF EMERGING GOOD PRACTICES

Presentation
Laurie B. Burke, Founder, Lora Group, LLC, and Former Director, Study Endpoints and Labeling Development, ONDIO, CDER, U.S. Food & Drug Administration, Silver Spring, MD, USA
Donald L. Patrick, Director, Seattle Quality of Life Group, University of Washington, Seattle, WA, USA
Marc Walton, Senior Scientific Director, Janssen Research and Development, Ashton, MD, USA
John Powers, Associate Clinical Professor of Medicine, School of Medicine Penfield House, George Washington University, Rockville, NJ, USA

 

F9 : THE DO’S AND DON’TS OF PERFORMING A SCOPING REVIEW

Presentation
Karen Freyer, Nutritionist & Nutrition Economist, School for Public Health and Primary Care (CAPHRI), Maastricht University, Zoetermeer, The Netherlands
Janos G. Pitter, Principal Researcher, Syreon Research Institute, Budapest, Hungary
Sheri Volger, Principal Clinical Scientist, Nestle Nutrition R&D, King of Prussia, PA, USA

 

F10 : USE AND MANAGEMENT OF BIG DATA IN HEALTH ECONOMICS AND OUTCOMES RESEARCH FOR CREATING BEST PRACTICES IN ASIA-PACIFIC: EXPERIENCES AND LESSONS LEARNED IN AUSTRALIA, JAPAN, SINGAPORE, SOUTH KOREA, AND TAIWAN

Presentation
Seungjin Bae, Associate Professor, Pharmacoeconomics and Outcomes Research, College of Pharmacy, Ewha Womans University, Seoul, South Korea
Presentation
Bruce Crawford, Senior Principal, Real-World Evidence Solutions, Japan & APAC, IMS Japan K.K., Minato-ku, Tokyo, Japan
Presentation
Chee-Jen Chang, Director & Professor, Clinical Informatics and Medical Statistics Research Center, Chang Gung University, TaoYuan, Taiwan
Presentation
Hwee Lin Wee, Assistant Professor, Saw Swee Hock School of Public Health, National University of Singapore, -, Singapore
Presentation
Joshua Byrnes, Research Fellow, Centre for Applied Health Economics, Griffith University, Queensland, Australia

 

F11 : PUBLIC ENGAGEMENT IN HEALTH CARE PRIORITY SETTING: EXPERIENCES AND CHALLENGES AT ENGAGING THE PUBLIC IN LATIN AMERICA

Presentation
Diego Rosselli, Professor of Health Economics, Clinical Epidemiology and Biostatistics, Medical School, Pontificia Universidad Javeriana, Bogota, Colombia
Presentation
Federico Augustovski, Director, Health Technology Assessment and Health Economic Department, Institute for Clinical Effectiveness and Health Policy (IECS), University of Buenos Aires, Buenos Aires, Argentina
Presentation
Aline Silveira Silva, Technologist, Executive Secretariat, CONITEC, Brazilian Ministry of Health, Brasilia, Brazil
Presentation
Jennifer Whitty, Professor of Health Economics, University of East Anglia, Norwich, UK

 

F12 : VALUE IN HEALTH FORUM ON PATIENT-FOCUSED BENEFIT-RISK ANALYSIS TO INFORM REGULATORY DECISIONS

Presentation
F. Reed Johnson, Senior Research Scholar, Preference Evaluation Research Group, Duke Clinical Research Institute, Durham, NC, USA
Deborah A. Marshall, Canada Research Chair, Health Services and Systems Research & Associate Professor, Department of Community Health Sciences, Faculty of Medicine, University of Calgary, Alberta Bone and Joint Health Institute, Calgary, AB, Canada
Shelby Reed, Associate Professor in Medicine, Duke Clinical Research Institute, Durham, NC, USA
Bennett Levitan, Senior Director, Benefit-Risk Assessment, Epidemiology, Janssen R&D, Titusville, NJ, USA
Axel C. Muhlbacher, Professor, Hochschule Neubrandenburg, Neubrandenburg, Germany

 

F13 : DEVELOPMENT AND APPLICATION OF MULTI-CRITERIA DECISION ANALYSIS IN CENTRAL & EASTERN EUROPE (CEE) IN COOPERATION WITH WESTERN COUNTRIES

Presentation
Oresta Piniazhko, PhD Candidate, & Assistant Professor, Department of Management and Economy of Pharmacy, Medicine Technology and Pharmacoeconomics, Danylo Halytsky Lviv National Medical University, Lviv, Ukraine
Presentation
Vladimir Zah, Health Economist, ZRx Outcomes Research Inc., Belgrade, Serbia
Presentation
Lubov Krasnova, Senior Researcher, Department of Hematology & Geriatrics, First Sechenov State Medical University, Moscow, Russian Federation
Presentation
Tamás Ágh, Principal Researcher, Syreon Research Institute, Budapest, Hungary

 

F14 : THE HEALTH AND ECONOMIC THREATS OF NON-COMMUNICABLE DISEASES IN THE MIDDLE EAST AND NORTH AFRICA

Presentation
Ola G. Al Ahdab Albannay, President, ISPOR United Arab Emirates Chapter and Pharmaceutical Advisor & Project Manager, Registration and Drug Control Department, Ministry of Health, Abu Dhabi, United Arab Emirates
Presentation
Daoud Al-Badriyeh, President, ISPOR Qatar Chapter and Assistant Professor, Qatar University, Doha, Qatar
Presentation
Mahmoud Diaa Elmahdawy, President, ISPOR Egypt Chapter, Director, AMAC Market Access, Novartis, Health Economics, Lecturer of Clinical and Hospital Pharmacy, Misr International University, Cairo, Egypt
Presentation
Christiane Maskineh, Executive Director, ISPOR Lebanon Chapter, Beirut, Lebanon
Presentation
Nasser Alqahtani, Head, Adverse Drug Reactions Evaluation Department - Pharmacovigilance Center, Saudi Food & Drug Authority, Riyadh, Saudi Arabia

 

EDUCATIONAL SYMPOSIA

BUDGET IMPACT ANALYSIS: AN ACCEPTABLE PART OF VALUE ASSESSMENTS OR A DISCORDANT CONCEPT?

Presentation
Peter J. Neumann, Professor & Director, Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies,Tufts Medical Center, Boston, MA, USA
Darius N. Lakdawalla, Quintiles Chair in Pharmaceutical Development and Regulatory Innovation; Professor, Sol Price School of Public Policy, School of Pharmacy, University of Southern California, Los Angeles, CA, USA
Steven D. Pearson, Founder and President, Institute for Clinical and Economic Review, Boston, MA, USA
Dan Leonard, President, National Pharmaceutical Council, Washington, DC, USA
Matt Salo, Executive Director, National Association of Medicaid Directors, Washington, DC, USA

 

ONCOLOGY THERAPIES: ARE WE REALLY INCREASING VALUE AND AFFORDABILITY WHILE KEEPING THE FOCUS ON PATIENT CARE?

Presentation
Timothy M Baker, Senior Health Economist, ICON Health Economics & Epidemiology, New York City, NY, USA
Elisabeth Fenwick, Principal of Health Economics, ICON Health Economics & Epidemiology, Abingdon, UK
Andrew Briggs, Visiting Investigator, Center for Health Policy and Outcomes, Department of Epidemiology & Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA & William R. Lindsey Chair of Health Economics & Health Technology Assessment, Institute of Health & Wellbeing, University of Glasgow, Glasgow, UK
Christopher Parker, Lead Health Economist, ICON Health Economics & Epidemiology, Abingdon, UK
Mark Sculpher, Professor of Health Economics, Centre for Health Economics & Director, Programme on Economic Evaluation and Health Technology Assessment, University of York, Heslington, York, UK

 

DRIVERS OF EFFECTIVENESS FOR INFORMED OUTCOMES-BASED AGREEMENTS

Presentation
Roman Casciano, Executive Vice President and Head, Value and Access, LASER Analytica, New York, NY, USA
Essy Mozaffari, Vice-President, Market Access, Chimerix Inc., Durham, NC, USA
Helene Karcher, Managing Vice-President, Global Head, Real World Modeling, LASER Analytica, London, UK
Christopher Bradbury, Senior Vice-President, Integrated Clinical Solutions & Specialty Pharmacy, Cigna Pharmacy Management, Bloomfield, CT, USA

 

PODIUM AND POSTER PRESENTATIONS


For contributed research podium and poster abstracts and released slide or poster presentations for the ISPOR 21st Annual International Meeting, see: the ISPOR Scientific Presentations Database an electronic database of nearly 44,500 research papers presented at ISPOR International Conference, ISPOR European Conference, and ISPOR Asia-Pacific & Latin America Conferences from 1998 to date.

  • ISPOR Scientific Presentations Database
  • Under Meeting select ISPOR 21st Annual International Meeting – Washington DC, USA
  • Select Search for all research podium and poster abstracts and available slide or poster presentations from the meeting. Alternatively search by disease/disorder, topic or subtopic.
OPEN MEETINGS
EDUCATIONAL FORUM
STUDENT SHOWCASE
Contact ISPOR @ info@ispor.org | View Legal Disclaimer
© 2018 International Society for Pharmacoeconomics and Outcomes Research.
All rights reserved under International and Pan-American Copyright Conventions.